Blood sugar control may boost chemo survival in pancreatic cancer patients

NCT ID NCT07272109

Not yet recruiting Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looks at whether actively treating diabetes with drugs like metformin or insulin can help people with metastatic pancreatic cancer live longer when they also receive standard chemotherapy. About 210 adults with both pancreatic cancer and diabetes will be enrolled. The goal is to see if better blood sugar control improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Metformin, insulin, or other anti-diabetic treatments
What this could lead to: If it works, this could show that managing blood sugar alongside chemotherapy helps people with pancreatic cancer live longer.
What could go wrong: This is a Phase 3 trial, but it only includes people with both pancreatic cancer and diabetes, so results may not apply to everyone. Adding anti-diabetic drugs may not improve survival and could cause side effects like low blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Shanghai Cancer Center

Shanghai, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.